Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Remazolam Besylate Combined With Remifentanil Analgesic Sedation on the Prognosis of Patients With Sepsis

NCT06731088 is registered in ClinicalTrials.gov with First Affiliated Hospital of Ningbo University as lead sponsor.

NCT NCT06731088
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06731088 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Remazolam Besylate Combined With Remifentanil Analgesic Sedation on the Prognosis of Patients With Sepsis
Lead sponsor
First Affiliated Hospital of Ningbo University
Phase
Phase 4
Overall status
Enrolling by invitation
Start date
January 1, 2025
Completion date
December 31, 2025
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sepsis